Advanced Biodesign

Pre-clinical

Paris, FranceFounded 2010a-biodesign.com

Advanced BioDesign is a French biotech founded in 2010 with a mission to treat chemotherapy-resistant cancers by targeting the ALDH1 enzyme family, a key driver of tumor drug resistance and immunomodulation. The company has progressed its lead small-molecule inhibitor, ABD-3001, into clinical trials for AML and has a promising pre-clinical pipeline for solid tumors. Its integrated strategy combines therapeutic inhibitors with a companion diagnostic, ALDESCREEN®, aiming to personalize treatment and improve outcomes for patients with resistant cancers.

Founded

2010

Focus

Small Molecules

AI Company Overview

Technology Platform

A platform for discovering and developing small-molecule inhibitors targeting the ALDH1 enzyme family to overcome chemotherapy resistance, target cancer stem cells, and modulate the tumor immune microenvironment.

Opportunities

Significant opportunities exist in expanding ABD-3001 into combination regimens and additional cancer types, advancing the more potent ABD-0171 into the clinic for solid tumors, and commercializing the ALDESCREEN® diagnostic as a companion test to guide therapy.

Partnerships with larger pharma companies for clinical development or commercialization are a likely growth vector.

Risk Factors

Key risks include clinical trial failure, the potential for unforeseen toxicities from ALDH1 inhibition, inability to secure sufficient funding to advance the pipeline, and emergence of competitive therapies targeting cancer drug resistance through other mechanisms.

Competitive Landscape

Competition includes other companies targeting cancer stem cells or drug resistance pathways, such as those focusing on other enzymatic targets or signaling pathways. Advanced BioDesign differentiates itself through its specific ALDH1 focus, clinical-stage asset, and proprietary diagnostic, aiming to create a targeted treatment paradigm for resistant cancers.